Revised forecast
Fiscal year ending March 2027 · Interim consolidated cumulative period and full yearPrevious forecast published 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In the domestic market, sales of products including PXB mice and PXB-cells grew, while in overseas markets, U.S. pharmaceutical companies continued to restrain research and development budgets, resulting in the loss of contract testing projects. In addition, the start of contract manufacturing and sales of fresh PXB-cells in the United States was delayed until the fourth quarter or later due to delays in quality checks. In light of the decline in revenue, the company revised its full-year revenue and profit plans downward.
| Item | Details |
|---|---|
| Net Sales | 671 (interim period) / 1,610 (full year) → 558 (interim actual) / 1,416 (revised full-year forecast)（-16.8% (interim period) / -12.1% (full year)） |
| Operating profit | -96 (interim period) / 85 (full year) → -119 (interim actual) / 20 (revised full-year forecast)（- (interim period) / -75.6% (full year)） |
| Ordinary income | -95 (interim period) / 87 (full year) → -120 (interim actual) / 25 (revised full-year forecast)（- (interim period) / -70.8% (full year)） |
| Profit attributable to owners of the parent | -98 (interim period) / 76 (full year) → -123 (interim actual) / 19 (revised full-year forecast)（- (interim period) / -74.7% (full year)） |
| Net income per share | -¥24.30 (interim period) / ¥18.90 (full year) → -¥30.36 (interim actual) / ¥4.78 (revised full-year forecast)（- (interim period) / - (full year)） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Interim consolidated cumulative period and full year |
| Publication date of previous forecast | 15 May 2026 |
| Previous-period results | Interim period: revenue of ¥756 million, operating income of ¥5 million, ordinary income of ¥16 million, interim net income attributable to owners of the parent of ¥12 million, and interim net income per share of ¥3.03. Full year: revenue of ¥1,565 million, operating income of ¥82 million, ordinary income of ¥131 million, net income attributable to owners of the parent of ¥125 million, and net income per share of ¥30.81. |
| Reason for the revision | In the domestic market, sales of products including PXB mice and PXB-cells grew, while in overseas markets, U.S. pharmaceutical companies continued to restrain research and development budgets, resulting in the loss of contract testing projects. In addition, the start of contract manufacturing and sales of fresh PXB-cells in the United States was delayed until the fourth quarter or later due to delays in quality checks. In light of the decline in revenue, the company revised its full-year revenue and profit plans downward. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the domestic market, sales grew as use of PXB mice and PXB-cells expanded, while in overseas markets, U.S. pharmaceutical companies, the company's major customers, continued to restrain research and development budgets, resulting in the loss of anticipated contract testing projects. In addition, the start of contract manufacturing and sales of fresh PXB-cells in the United States was delayed until the fourth quarter or later due to delays in quality checks. Despite reducing expenses in response to the decline in revenue, the company revised its profit forecast downward.